Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine

We evaluated the immune response against the Omicron variant after mRNA-based COVID-19 booster vaccination in medical students. We prospectively enrolled medical students who received two primary doses of the mRNA-1273 vaccine. The neutralizing response and the SARS-CoV-2-specific T-cell response wa...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-12, Vol.10 (12), p.2102
Main Authors: Chung, Hyemin, Lee, Jongsung, Minn, Kyungrok, Lee, Jiyoung, Yun, Soyoung, Park, Joung Ha, Kim, Min-Chul, Choi, Seong-Ho, Chung, Jin-Won
Format: Article
Language:English
Subjects:
Antibodies
Blood
booster
Communication
Coronaviruses
COVID-19
COVID-19 vaccines
Enzymes
Immune response
Immune system
Immunity
Immunogenicity
Immunoglobulin G
Immunoglobulins
Infections
Lymphocytes T
Medical examination
medical school students
Medical students
Messenger RNA
Methods
mRNA
Neutralizing
neutralizing antibody response
Omicron
School enrollment
Severe acute respiratory syndrome coronavirus 2
Students
T cells
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the immune response against the Omicron variant after mRNA-based COVID-19 booster vaccination in medical students. We prospectively enrolled medical students who received two primary doses of the mRNA-1273 vaccine. The neutralizing response and the SARS-CoV-2-specific T-cell response was evaluated. A total of 56 serum samples were obtained before booster vaccination. Nineteen students (33.9%) developed COVID-19 two months after booster vaccination. Of 56 students, 35 students (12 infected and 23 uninfected) were available for blood sampling four months after booster vaccination. In comparison with uninfected students, infected students showed a significantly higher level of SARS-CoV-2-specific IgG (5.23 AU/mL vs. 5.12 AU/mL, p < 0.001) and rate of neutralizing response (96.22% vs. 27.18%, p < 0.001) four months after booster vaccination. There was no significant difference in the SARS-CoV-2-specific T-cell response. Among 23 infection-naive students, the neutralizing response was significantly higher in those who received the mRNA-1273 booster than in those who received the BNT162b2 booster (69.07% vs. 26.43%, p = 0.02). In our study, booster vaccination with mRNA-1273 instead of BNT162b2 was significantly associated with a higher neutralizing response.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10122102